FADS2 and cancer: Additionally, FADS2 was remarkably upregulated across a wide range of BRCA patient characteristics, including age (21–100 years), all cancer stages (1–4), races (Caucasian, African-American, and Asian), nodal metastasis status (N0–3), histological subtypes (IDC, other, mucinous, metaplastic, and medullary), and menopausal status (premenopause, peri-menopause, and postmenopause) (Fig. 3G–L).